Telix and Atlab Working to Develop Antibody for Radioimmunotherapy in Advanced Cancers

Telix and Atlab Working to Develop Antibody for Radioimmunotherapy in Advanced Cancers
Telix Pharmaceuticals and Atlab Pharma are working together to develop and possibly market huJ591, a monoclonal antibody to be used in radioimmunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the agreement, Telix will financially support the production and clinical development of huJ591, an anti-PSMA antibody linked to radioactive lutetium-177 (Lu-177) and astatine-211 (At-211). It also has exclusive options to acquire Atlab. The partners are planning a Phase 2b trial to evaluate the effectiveness of the radioactive huJ591 antibody in treating patients with metastatic prostate cancer, both those receiving standard chemotherapy and those who are not. “Radioimmunotherapy is finally starting to hit its stride and garner the interest
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *